High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
about
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplificationHER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.Metastatic breast cancer: The Odyssey of personalization.Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting.Contributions of Thyroid Hormone to Cancer MetastasisRelationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
P2860
Q27853172-C5C3F889-BA99-426B-ABFF-C406F8D784E2Q34010867-537BD9B4-EB3C-4679-97C2-7A7655505D67Q35699689-6C9B2574-3834-4A21-875C-33B8EEC3B194Q35863066-416D0DFF-8FB5-4BBD-A562-87893001E221Q36087126-3F1B3554-5080-41C7-B291-E7F1605D3A4CQ37665397-CC1D1F0D-2AA5-46EA-B670-802D46C745A7Q38901163-79BA4293-C14E-44A4-8E3A-9491BED002F3Q53581875-FD111139-C834-47A5-BDDB-90DCC1F71D9BQ55332501-90A4CB03-FD3F-4BEB-891F-5EDC572A18F7Q58717087-25213F42-9E3C-4E62-B84A-52091A36F4E4Q58801931-E1FF9294-D8D1-4315-910B-BDE768403033
P2860
High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@en
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@nl
type
label
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@en
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@nl
prefLabel
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@en
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@nl
P2093
P2860
P356
P1476
High-level ERBB2 gene amplific ...... red in the metastatic setting.
@en
P2093
Christian F Singer
Christoph C Zielinski
Ernst Kubista
Eva-Maria Fuchs
Gernot Hudelist
Reinhard Horvat
Wolfgang J Köstler
P2860
P304
P356
10.1002/IJC.28660
P577
2014-01-28T00:00:00Z